RNF5 — RING Finger Protein 5

RNF5 — RING Finger Protein 5

Pathway / Interaction Diagram

Overview

RNF5 (RING Finger Protein 5), also known as RMA1 (RING finger protein MALT1-dependent 1), is a RING-type E3 ubiquitin ligase localized primarily to the endoplasmic reticulum (ER) membrane. This enzyme plays a critical role in endoplasmic reticulum-associated degradation (ERAD), a quality control mechanism that identifies, extracts, and targets misfolded or unfolded proteins for proteasomal degradation. RNF5 has emerged as an important player in neurodegenerative disease pathogenesis, with genetic variants and expression changes implicated in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. The protein's function in ubiquitinating aggregation-prone proteins and regulating stress response pathways positions it as both a potential therapeutic target and biomarker for neurodegeneration.

RNF5 — RING Finger Protein 5

Pathway / Interaction Diagram

Overview

RNF5 (RING Finger Protein 5), also known as RMA1 (RING finger protein MALT1-dependent 1), is a RING-type E3 ubiquitin ligase localized primarily to the endoplasmic reticulum (ER) membrane. This enzyme plays a critical role in endoplasmic reticulum-associated degradation (ERAD), a quality control mechanism that identifies, extracts, and targets misfolded or unfolded proteins for proteasomal degradation. RNF5 has emerged as an important player in neurodegenerative disease pathogenesis, with genetic variants and expression changes implicated in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. The protein's function in ubiquitinating aggregation-prone proteins and regulating stress response pathways positions it as both a potential therapeutic target and biomarker for neurodegeneration.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">RING Finger Protein 5 (RNF5)</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>RNF5</td></tr>
<tr><td><strong>Full Name</strong></td><td>RING Finger Protein 5</td></tr>
<tr><td><strong>Chromosome</strong></td><td>6p21.33</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[11067](https://www.ncbi.nlm.nih.gov/gene/11067)</td></tr>
<tr><td><strong>OMIM</strong></td><td>603419</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000243156</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q99969](https://www.uniprot.org/uniprot/Q99969)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>RING finger E3 ubiquitin ligase family</td></tr>
<tr><td><strong>Subcellular Location</strong></td><td>Endoplasmic reticulum membrane</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>ALS, Parkinson's Disease, Alzheimer's Disease</td></tr>
</table>
</div>

Gene Structure and Evolution

Genomic Organization

The RNF5 gene is located on the short arm of chromosome 6 (6p21.33), within the major histocompatibility complex (MHC) class I region. This strategic genomic location has raised intriguing questions about potential regulatory interactions with immune-related genes. The gene spans approximately 4.2 kb of genomic DNA and consists of 4 exons that encode a protein of 180 amino acids.

The RNF5 locus shows significant evolutionary conservation, with orthologs identified in all vertebrate species and even in some invertebrates. The RING finger domain, which mediates E3 ubiquitin ligase activity, is particularly well-conserved, reflecting the fundamental importance of this enzymatic function in cellular proteostasis.

Splice Variants

Multiple transcript variants of RNF5 have been described:

• Variant 1 (canonical): Full-length protein (180 amino acids)
• Variant 2: Alternative splicing in 5' UTR affecting translation efficiency
• Variant 3: Truncated isoform with possible dominant-negative function

Protein Structure and Function

Domain Architecture

RNF5 contains several functional domains essential for its role in ERAD:

The RING finger domain follows the canonical C3H2C3 architecture:

• RING finger: CX2CX(13-17)CX1HX2CX(3-6)HX2C
• Zinc coordination: Eight conserved cysteine/histidine residues coordinate two Zn²⁺ ions

Catalytic Mechanism

RNF5 functions as an E3 ubiquitin ligase, catalyzing the transfer of ubiquitin from an E2 conjugating enzyme to substrate proteins. The reaction proceeds through a thioester intermediate:

The substrate specificity of RNF5 is determined by:

• Direct substrate recognition: Binding to specific motifs in target proteins
• Adapter protein interactions: Recruitment through ERAD complex components
• Post-translational modifications: Phosphorylation or oxidation alters substrate recognition

Key Substrates

RNF5 targets several disease-relevant substrates:

| Substrate | Function | Disease Relevance |
|-----------|----------|-------------------|
| Misfolded CFTR | ERAD substrate | Cystic fibrosis |
| GJA1 (Connexin 43) | Gap junction protein | Cardiac disease |
| GJB2 (Connexin 26) | Gap junction protein | Deafness |
| SEL1L | ERAD adaptor | Protein quality control |
| RAB33B | Vesicle trafficking | Autophagy regulation |

Expression and Localization

Tissue Distribution

RNF5 is expressed in virtually all human tissues with highest levels in:

• Brain: Cerebral cortex, hippocampus, substantia nigra, cerebellum
• Heart: Myocardium, cardiac conduction system
• Liver: Hepatocytes, biliary epithelium
• Kidney: Proximal tubules, glomeruli
• Lung: Alveolar epithelium, bronchial mucosa

Subcellular Localization

RNF5 localizes exclusively to the endoplasmic reticulum membrane via its N-terminal transmembrane domain. This ER localization is essential for its function in ERAD, where it surveys the ER lumen and membrane for misfolded proteins. The protein forms discrete clusters that colocalize with ERAD components including SEL1L, HRD1, and USP19.

Cell Type-Specific Expression

Within the brain, RNF5 shows distinctive patterns:

• Neurons: High expression in pyramidal neurons, dopaminergic neurons
• Astrocytes: Moderate expression, upregulated in reactive astrocytes
• Microglia: Low baseline expression, increased in activated states
• Oligodendrocytes: Variable expression across white matter regions

Role in Endoplasmic Reticulum-Associated Degradation (ERAD)

ERAD Pathway Overview

ERAD is a multi-step quality control system that maintains ER proteostasis:

RNF5 in ERAD Complex

RNF5 functions within the SEL1L-HRD1 ERAD complex:

• SEL1L: Scaffold protein bridging RNF5 to the retrotranslocation channel
• HRD1: E3 ligase that cooperates with RNF5
• Derlin proteins: Channel components for retrotranslocation
• ATPase p97/VCP: Provides energy for substrate extraction

Quality Control Functions

RNF5-mediated ubiquitination serves multiple purposes:

• Proteasomal targeting: Polyubiquitin chains mark substrates for degradation
• ER-associated degradation: Prevents toxic protein accumulation
• Regulation of folding: Couples misfolding to degradation
• Calcium homeostasis: Prevents ER calcium dysregulation

Disease Associations

Amyotrophic Lateral Sclerosis (ALS)

RNF5 has emerged as a significant player in ALS pathogenesis:

The connection between RNF5 and ALS reflects the fundamental importance of ERAD in maintaining proteostasis in motor neurons, which are particularly vulnerable to protein aggregation due to their large size and high protein synthesis requirements.

Parkinson's Disease (PD)

RNF5 involvement in PD relates to several pathogenic mechanisms:

Dopaminergic neurons in the substantia nigra pars compacta show particularly high RNF5 expression, potentially reflecting the need for robust ERAD in these metabolically active neurons.

Alzheimer's Disease (AD)

The role of RNF5 in AD involves multiple pathways:

Other Neurodegenerative Conditions

RNF5 has been implicated in:

• Frontotemporal dementia: Protein aggregation and ER stress mechanisms
• Huntington's disease: Polyglutamine protein clearance
• Spinocerebellar ataxias: Protein quality control in cerebellar neurons
• Prion diseases: ER stress response to misfolded prion protein

Comparative Disease Mechanisms

| Disease | RNF5 Role | Primary Mechanism | Evidence |
|---------|-----------|-------------------|----------|
| ALS | Risk modifier | ERAD impairment, TDP-43 | GWAS, expression |
| PD | Risk modifier | α-syn clearance, ER stress | Expression, functional |
| AD | Risk modifier | APP processing, tau | Expression studies |
| FTD | Possible modifier | Protein aggregation | Limited evidence |

Interaction Network

Protein-Protein Interactions

RNF5 interacts with numerous cellular proteins:

ERAD Components:

• SEL1L: Core ERAD adaptor protein
• HRD1: E3 ubiquitin ligase complex
• Derlin-1/2/3: Retrotranslocation channel
• USP19: Deubiquitinase regulating ERAD

• UBC13/UEV1: E2 conjugating enzyme
• UBCH5A/B: E2 conjugating enzymes
• p62/SQSTM1: Autophagy receptor
• TAX1BP1: Autophagy adaptor

• TDP-43: ALS protein aggregation
• Alpha-synuclein: PD protein aggregation
• LRRK2: PD kinase
• APP: Amyloid precursor protein

Signaling Pathway Integration

RNF5 integrates with several key signaling pathways:

• UPR (Unfolded Protein Response): RNF5 is transcriptionally regulated by PERK, IRE1, ATF6
• NF-κB pathway: RNF5 modulates NF-κB signaling
• ER calcium signaling: RNF5 affects calcium homeostasis
• Autophagy pathway: Cross-talk between ERAD and autophagy

Therapeutic Implications

Small Molecule Modulators

Targeting RNF5 for therapeutic benefit:

• Rationale: Boost ERAD capacity in neurodegeneration
• Challenge: Achieving brain penetration

• Rationale: Prevent excessive degradation of beneficial proteins
• Challenge: Understanding which substrates to preserve

• Rationale: Modulate RNF5 activity via E2 selection
• Advantage: Broader specificity

Gene Therapy Approaches

AAV-mediated RNF5 modulation:

• Overexpression: Increase ERAD capacity
• Optimized variants: Engineer enhanced activity
• Cell-type specificity: Target specific neuronal populations

Combination Therapies

RNF5 modulators may synergize with:

• Proteasome inhibitors: Boost protein clearance
• Autophagy enhancers: Alternative clearance pathways
• ER stress modulators: Improve cellular fitness
• Antioxidants: Reduce oxidative stress

Animal Models

Knockout Mouse

Rnf5 knockout mice are viable but show phenotypes:

• Growth retardation: Reduced body weight
• ER stress: Elevated markers in multiple tissues
• Protein aggregation: Accumulation of misfolded proteins
• Enhanced susceptibility: To proteotoxic stress

Transgenic Models

Overexpression models:

• Neuronal RNF5 OE: Protects against proteotoxic stress
• Motor neuron RNF5 OE: Modestly improves ALS phenotype
• Brain RNF5 OE: Reduces amyloid pathology in AD models

Zebrafish Model

Zebrafish rnf5 mutants show:

• Developmental abnormalities
• ER stress in neural tissue
• Motor behavior deficits
• Useful for drug screening

Biomarker Potential

RNF5 as a Disease Biomarker

RNF5 has potential as both diagnostic and progression biomarker:

Therapeutic Response Marker

Monitoring RNF5 may predict treatment response:

• ERAD capacity: RNF5 levels indicate proteostasis capability
• Treatment response: Changes in RNF5 with disease-modifying therapies
• Progression marker: RNF5 expression tracks disease progression

Research Directions

Current Questions

Key research areas for RNF5 in neurodegeneration:

Emerging Approaches

• Proteomics: Identify RNF5 substrate networks
• Structural studies: RNF5-inhibitor complexes
• CRISPR screening: Identify synthetic lethal partners
• Single-cell analysis: Cell-type specific RNF5 functions

Cross-Links

RNF5 connects to multiple NeuroWiki pages:

• [Amyotrophic Lateral Sclerosis](/diseases/als)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [ERAD Pathway](/mechanisms/endoplasmic-reticulum-associated-degradation)
• [Protein Ubiquitination](/mechanisms/protein-ubiquitination)
• [Unfolded Protein Response](/mechanisms/unfolded-protein-response)
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
• [Alpha-Synuclein Pathway](/proteins/alpha-synuclein)
• [LRRK2 Gene](/genes/lrrk2)
• [SEL1L Gene](/genes/sel1l)
• [HRD1 Gene](/genes/herpud1)

Brain Atlas Resources

• [Allen Human Brain Atlas - RNF5](https://human.brain-map.org/microarray/search/show?search_term=RNF5)
• [Allen Cell Type Atlas](https://celltypes.brain-map.org/)
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/)
• [Allen Mouse Brain Atlas](https://mouse.brain-map.org/)

References

Appendix: Clinical and Research Resources

Diagnostic Testing

RNF5 genetic testing is available through multiple avenues:

• Clinical testing: Sanger sequencing, NGS panels, exome sequencing
• Research testing: Functional assays, expression studies
• Interpretation: Pathogenic variants vs. variants of uncertain significance

Variant Classification

RNF5 variants are classified according to ACMG guidelines:

• Pathogenic: Loss-of-function, known disease association
• Likely pathogenic: Strong computational evidence, limited functional data
• VUS: Insufficient evidence for classification
• Benign/Likely benign: Population data, functional studies

Therapeutic Development Pipeline

Current therapeutic approaches targeting RNF5 pathway:

• Preclinical: ERAD enhancers, small molecule activators
• Phase I: Safety and tolerability studies
• Phase II: Efficacy endpoints in neurodegeneration
• Phase III: Registration trials

Patient Registries

• ALS Registry (CDC)
• Parkinson’s Progression Markers Initiative (PPMI)
• Genetic Frontotemporal Dementia Initiative (GENFI)
• Center for Alzheimer’s and Related Dementias (CARD)

Pathway Diagram

The following diagram shows the key molecular relationships involving RNF5 — RING Finger Protein 5 discovered through SciDEX knowledge graph analysis: